Enhancement of the in vivo osteogenic potential of marrow/hydroxyapatite composites by bovine bone morphogenetic protein.
A composite of marrow mesenchymal stem cells and porous hydroxyapatite (HA) has in vivo osteogenic potential. To investigate factors enhancing the osteogenic potential of marrow/HA composites, we prepared a bone morphogenetic protein (BMP) fraction from the 4M guanidine extract of bovine bone by heparin-sepharose affinity chromatography. Marrow/HA composites or composites containing marrow mesenchymal stem cells, BMP, and HA (marrow/BMP/HA composites) were implanted subcutaneously in 7-week-old male Fischer rats. BMP/HA composites and HA alone were also implanted. The implants were harvested after 2, 4, or 8 weeks and were prepared for histological and biochemical studies. Histological examination showed obvious de novo bone formation together with active osteoblasts at 2 weeks, as well as more extensive bone formation at 4 and 8 weeks in many pores of the marrow/BMP/HA composites. The marrow/HA composites did not induce bone formation at 2 weeks, but there was moderate bone formation at 4 weeks. At 2 weeks, only marrow/BMP/HA composites resulted in intensive osteogenic activity, judging from alkaline phosphatase and osteocalcin expression at both the protein and gene levels. These results indicate that the combination of marrow mesenchymal stem cells, porous HA, and BMP synergistically enhances osteogenic potential, and may provide a rational basis for their clinical application, although further in vivo experiment is needed.
Noshi
T
T
Departments of Oral and Maxillofacial Surgery, Nara Medical University, Kashihara City, Nara 634-8522, Japan.
Yoshikawa
T
T
Ikeuchi
M
M
Dohi
Y
Y
Ohgushi
H
H
Horiuchi
K
K
Sugimura
M
M
Ichijima
K
K
Yonemasu
K
K
D000469:Alkaline Phosphatase / Q000096:biosynthesis / Q000235:genetics; D000818:Animals; D021522:Bioartificial Organs; D001672:Biocompatible Materials / Q000494:pharmacology*; D016026:Bone Marrow Transplantation; D019485:Bone Morphogenetic Proteins / Q000494:pharmacology*; D018786:Bone Substitutes / Q000737:chemistry / Q000494:pharmacology*; D002417:Cattle; D002516:Ceramics / Q000737:chemistry / Q000494:pharmacology*; D017886:Durapatite / Q000494:pharmacology*; D004790:Enzyme Induction; D020869:Gene Expression Profiling; D007527:Isoenzymes / Q000096:biosynthesis / Q000235:genetics; D008297:Male; D008422:Materials Testing; D008648:Mesoderm / Q000166:cytology*; D018919:Neovascularization, Physiologic; D016348:Osseointegration / Q000187:drug effects*; D010006:Osteoblasts / Q000166:cytology / Q000378:metabolism; D015675:Osteocalcin / Q000096:biosynthesis / Q000235:genetics; D016062:Porosity; D019736:Prostheses and Implants; D012333:RNA, Messenger / Q000096:biosynthesis; D051381:Rats; D011916:Rats, Inbred F344; D033581:Stem Cell Transplantation
D001672:Biocompatible Materials; D019485:Bone Morphogenetic Proteins; D018786:Bone Substitutes; D007527:Isoenzymes; D012333:RNA, Messenger; D015675:Osteocalcin; D017886:Durapatite; D000469:Alkaline Phosphatase